Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2023 Financial Results
November 08, 2023 07:00 ET
|
Cullinan Oncology, Inc.
Cullinan to provide clinical data updates on three novel targeted oncology programs and complete enrollment in the pivotal Phase 2b portion of the zipalertinib REZILIENT1 study in 2024 Initial...
Cullinan Oncology to Present Data Demonstrating Progress Across Its Broad Immunotherapy-Pipeline at SITC 2023
November 03, 2023 12:01 ET
|
Cullinan Oncology, Inc.
Five abstracts accepted for poster presentation at the Society for Immunotherapy of Cancer 2023 Annual Meeting Preliminary clinical biomarker data for anti-MICA/B antibody, CLN-619, supports proposed...
Cullinan Oncology to Participate in Upcoming Investor Conferences
October 30, 2023 08:00 ET
|
Cullinan Oncology, Inc.
CAMBRIDGE, Mass., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan Oncology”) a biopharmaceutical company focused on modality-agnostic targeted oncology therapies,...
Cullinan Oncology to Participate in Upcoming Investor Conferences
September 06, 2023 08:00 ET
|
Cullinan Oncology, Inc.
CAMBRIDGE, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan Oncology”) a biopharmaceutical company focused on modality-agnostic targeted oncology...
Cullinan Oncology Provides Corporate Update and Reports Second Quarter 2023 Financial Results
August 10, 2023 07:00 ET
|
Cullinan Oncology, Inc.
Phase 3 first-line study of zipalertinib in EGFR exon 20 insertion mutation non-small-cell lung cancer (NSCLC) patients (REZILIENT-3) open to enrollment Initial monotherapy clinical data for...
Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-978, a Novel CD19xCD3 T cell Engager, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
August 09, 2023 07:00 ET
|
Cullinan Oncology, Inc.
CAMBRIDGE, Mass., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today announced that...
Cullinan Oncology to Participate in Upcoming Investor Conferences
July 31, 2023 08:00 ET
|
Cullinan Oncology, Inc.
CAMBRIDGE, Mass., July 31, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan Oncology”) a biopharmaceutical company focused on modality-agnostic targeted oncology therapies,...
Cullinan Oncology to Present First Monotherapy Clinical Data for CLN-619, a Novel Anti-MICA/B Antibody, at ASCO 2023
May 25, 2023 17:00 ET
|
Cullinan Oncology, Inc.
CLN-619 demonstrated monotherapy activity across a range of tumor types, including in patients whose cancer had progressed on checkpoint inhibitor therapy Initial data indicate an...
Cullinan Oncology Provides Corporate Update and Reports First Quarter 2023 Financial Results
May 11, 2023 16:01 ET
|
Cullinan Oncology, Inc.
Zipalertinib pivotal trial now enrolling at the 100mg BID dose only First clinical data for CLN-049 and CLN-619 to be reported at EHA 2023 Congress and ASCO 2023 Annual Meeting,...
Cullinan Oncology to Present First Clinical Data Evaluating Novel Anti-MICA/B Antibody, CLN-619, in Patients with Advanced Solid Tumors at ASCO 2023
April 26, 2023 10:08 ET
|
Cullinan Oncology, Inc.
CAMBRIDGE, Mass., April 26, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today...